{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:51:53Z","timestamp":1761155513824},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.jash.2011.08.003","type":"journal-article","created":{"date-parts":[[2011,10,2]],"date-time":"2011-10-02T10:37:41Z","timestamp":1317551861000},"page":"498-504","source":"Crossref","is-referenced-by-count":18,"title":["Validation of a therapeutic scheme for the treatment of resistant hypertension"],"prefix":"10.1016","volume":"5","author":[{"given":"Julian","family":"Segura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Cerezo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Garcia-Donaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Praga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"de la Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2011.08.003_bib1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.08.003_bib2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.jacc.2008.08.036","article-title":"Resistant hypertension: an overview of evaluation and treatment","volume":"52","author":"Sarafidis","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2011.08.003_bib3","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/01.HYP.31.2.712","article-title":"Prognostic value of ambulatory blood pressure monitoring in refractory: a prospective study","volume":"31","author":"Redon","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.08.003_bib4","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"De la Sierra","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.08.003_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.08.003_bib6","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/HJH.0b013e32833d4c99","article-title":"Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system","volume":"28","author":"Alvarez-Alvarez","year":"2010","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","article-title":"The effect of low-dose spironolactone on resistant hypertension","volume":"4","author":"Engbaek","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2011.08.003_bib9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2011.08.003_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0b013e3282f4b3e6","article-title":"Primary aldosteronism: an update on screening, diagnosis and treatment","volume":"26","author":"Rossi","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib11","first-page":"447","article-title":"Primary aldosteronism - part I: prevalence, screening, and selection of cases for adrenal vein sampling","volume":"21","author":"Rossi","year":"2008","journal-title":"J Nephrol"},{"key":"10.1016\/j.jash.2011.08.003_bib12","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/837817","article-title":"Aldosteronism and resistant hypertension","author":"Acelajado","year":"2011","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","article-title":"Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study","volume":"55","author":"Gaddam","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.08.003_bib14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jash.2011.08.003_bib15","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1097\/HJH.0b013e32833e1150","article-title":"Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database","volume":"28","author":"Parati","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2165\/00003495-199550030-00009","article-title":"A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease","volume":"50","author":"Haria","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.jash.2011.08.003_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(10)60235-8","article-title":"Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis","volume":"375","author":"Webb","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2011.08.003_bib18","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2011.08.003_bib19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2011.08.003_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ajh.2010.1","article-title":"Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium","volume":"23","author":"Ernst","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/HYPERTENSIONAHA.110.161505","article-title":"Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis","volume":"57","author":"Dorsch","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.08.003_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":"Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.08.003_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","article-title":"Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial","volume":"26","author":"Andersen","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1755-5922.2010.00148.x","article-title":"Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial","volume":"28","author":"Andersen","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jash.2011.08.003_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized double-blind comparator trial with hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2011.08.003_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/jhh.2010.38","article-title":"Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome","volume":"25","author":"Krone","year":"2011","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib27","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2165\/11204360-000000000-00000","article-title":"Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension","volume":"70","author":"Duggan","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jash.2011.08.003_bib28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1185\/03007990902785845","article-title":"Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension","volume":"25","author":"Littlejohn","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jash.2011.08.003_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lfs.2009.11.020","article-title":"Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control","volume":"86","author":"Ferrario","year":"2010","journal-title":"Life Sci"},{"key":"10.1016\/j.jash.2011.08.003_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/157488711795177912","article-title":"Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition","volume":"6","author":"Alfie","year":"2011","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.jash.2011.08.003_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-7061(96)00301-9","article-title":"Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients","volume":"10","author":"Alderman","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2011.08.003_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1254\/jphs.10R04FM","article-title":"New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren","volume":"113","author":"Ichihara","year":"2010","journal-title":"J Pharmacol. Sci"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171111002014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171111002014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:27:11Z","timestamp":1543516031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171111002014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1933171111002014"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2011.08.003","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}